Merck Sharp + Dohme Corp.

Merck Canada Inc.

Brendan O'Boyle

Kevin J Wilson

Phieng Siliphaivanh

Umar Faruk Mansoor

Matthew H Daniels

Michael D Altman

Xianhai Huang

David James Witter

Jongwon Lim

Alan B Northrup

David L Sloman

Christopher W Boyce

Ryan D Otte

Andrew M Haidle

Michael Hale Reutershan

Christian Fischer

John Michael Ellis

Wei Zhou

Kaleen Konrad Childers

Salem Fevrier

Danielle Falcone

Kathryn Ann Lipford

Joseph A Kozlowski

Maria Emilia Di Francesco

Daniel Guay

Joey Lee Methot

Michelle R Machacek

Solomon D Kattar

David Joseph Guerin

Raman Kumar Bakshi

Milana M Maletic

Brian M Andresen

Kenneth L Arrington

Corey E Bienstock

Anthony Donofrio

Kerrie Spencer

Eric Thomas Romeo

Adam J Schell

Ravi Kurukulasuriya

Dilrukshi Vitharana

Ganesh Babu Karunakaran

Peng Zhang

Fang Liu

Alan B Cooper

Joseph Michael Kelly

Ling Tong

Gerald Wayne Shipps, Jr

Yves Ducharme

B Wesley Trotter

Lingyun Wu

Alessia Petrocchi

Yongqi Deng

Tony Siu

Xiaolei Gao

Catherine M White

Lei Chen

Jayaram R Tagat

Matthew Christopher

Jonathan B Grimm

Sandra Lee Knowles

Binyuan Sun

Brandon Mitsuo Taoka

Ron Ferguson

Jason Burch

Sobhana Babu Boga

Christian Beaulieu

Yuan Liu

Brandon D Cash

Hugh Y Zhu

Xiaohua Huang

Liang Zhu

Bernard Cote

Elizabeth Helen Kelley

Shuyi Tang

Abdul-Basit Alhassan

Hyun Chong Woo

Chaomin Li

Judson E Richard

Sie-Mun Lo

Ronald D Ferguson

Angie R Angeles

Xin Yao

Jayanth Thiruvellore Thatai

Kristina Dupont-Gaudet

Bidhan A Shinkre

The invention provides certain thiazole-substituted aminopyridine compounds of the Formula (I) (I) or pharmaceutically acceptable salts thereof, wherein R, R, R, R, R, R, C, and the subscript t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk). 

Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors

Provided are triazole derivatives of Formula I which are potent inhibitors of spleen tyrosine kinase and pharmaceutical composition. The triazole derivatives are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD, rheumatoid arthritis, and cancer.

Triazolyl derivatives as Syk inhibitors

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). 

Compounds that are ERK inhibitors

Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0). 

The present invention provides a compound of the Formula I: (Formular I should be inserted here) or a pharmaceutically acceptable salt, solvate or ester thereof, wherein R, R1, R2 and R3 are as defined herein. The compounds are ERK inhibitors. Also disclosed are pharmaceutical compositions comprising the above compounds and methods of treating cancer using the same. 

Heterocyclic compounds as ERK inhibitors

The present invention provides novel pyrimidine amines of formula (I) which are potent inhibitors of spleen tyrosine kinase, and are useful in the treatment and prevention of diseases mediated by said enzyme, such as asthma, COPD and rheumatoid arthritis.

Aminopyrimidines as SYK inhibitors

Growing community of inventors

Boston, MA, United States of America

Brendan O'Boyle